Core Viewpoint - The article discusses the regulatory response to the Kangaroo Mom brand, which has faced scrutiny over its marketing practices related to cosmetics for pregnant consumers, highlighting the importance of compliance in the cosmetics industry [1][4]. Group 1: Regulatory Actions - The Guangzhou Market Supervision Administration established a verification team to investigate Kangaroo Mom Group following media reports about its cosmetic sales practices [1]. - The investigation found that the company's production practices were compliant, with 38 batches of cosmetics tested over the past three years meeting safety standards [1]. - The administration has criticized the company for improper marketing statements and has urged it to implement corrective measures [1]. Group 2: Industry Trends - The rise of the "she economy" has led to increased consumer interest in cosmetics among pregnant women, which has put brands like Kangaroo Mom under scrutiny for compliance with marketing regulations [4]. - Kangaroo Mom acknowledged the issue of vague statements made by some live-streaming hosts and has committed to internal rectification and training for its staff [4].

Core Viewpoint - The article discusses the rapid decline of exosomes in the consumer market following the 3·15 exposure event, highlighting the need for regulation in the medical beauty and cosmetics industry while also recognizing the scientific value and potential applications of exosome technology [2][6][21]. Summary by Sections Exosome Market Dynamics - After the 3·15 event, exosome-related products were quickly removed from platforms like Xiaoyang and Tmall, indicating a swift shift from hype to scrutiny in the market [2]. - The exosome industry in China showed strong growth, with a market size reaching 2.279 billion yuan in 2024, reflecting a year-on-year increase of 22.72% [20]. Regulatory and Ethical Concerns - The 3·15 exposure revealed various illegal practices surrounding exosome applications, including unauthorized production and misleading marketing claims, which harm consumer rights and violate regulatory standards [4][21]. - The article emphasizes the need for industry regulation to address these market irregularities while also acknowledging the scientific exploration of exosomes as a significant biomedical research direction [6][25]. Scientific Background and Development - Exosomes were initially dismissed as "cellular waste" until significant discoveries in the 1990s and 2000s revealed their role in intercellular communication and immune activation, leading to a surge in research interest [9][10]. - The Nobel Prize awarded in 2013 for discoveries related to vesicle transport mechanisms further propelled exosome research, establishing their importance in drug development [10][13]. Commercialization Challenges - The transition from laboratory research to consumer products is complex and lengthy, often requiring multiple stages of research and regulatory approval [16][18]. - Currently, most exosome projects are still in the application research and technology validation phase, with only a few advancing to clinical trials [19][20]. Future Outlook - The article suggests that the recent exposure may serve as a necessary correction for the industry, allowing for a clearer path for genuine innovation and compliance in the use of exosome technology [23][25]. - It highlights the importance of addressing foundational scientific questions and regulatory compliance to ensure the safe and effective application of exosomes in consumer products [27][28].

Sales Channel Optimization - The offline sales channel optimization is progressing as expected, with significant improvements in channel quality and management capabilities [2] - The company is expanding its offline sales team to establish a solid foundation for long-term operations [2] - The shift from traditional distribution to value-driven sales models aims to enhance profitability and growth potential of offline channels [2][3] Market Competition - The company views strong competitors as catalysts for growth, providing valuable learning experiences [3] - The offline profit margins are substantial, prompting proactive adjustments to adapt to intense market competition [3] Revenue Expectations - The company is optimistic about recovering offline revenue in 2026, having made adequate preparations in 2025 [4] - Continuous efforts will be made to expand the offline market in 2026 [4] Online Sales Performance - The largest online sales platforms are Douyin and Tmall, with both showing similar sales volumes [5] - Other platforms, such as JD.com, have also shown significant growth in 2025 [5] Product Development - The company has high expectations for the upcoming medical product, the seaweed sugar repair patch, which is still in the pre-launch phase [5] - The lactose acid mask launched previously performed excellently in 2025, meeting sales expectations [5] - The company is preparing to submit materials for the approval of a new collagen product, with clinical trials completed [6]

Summary of Key Points from Conference Call Records Industry Overview - The consumer sector, particularly the cyclical consumption segment, is showing signs of bottoming out, with potential for rebound or reversal in demand. This is supported by positive trends in the restaurant industry, which serves as a key reference point [2][2] - The restaurant industry is experiencing a slowdown in price wars, with companies like McDonald's and KFC implementing slight price increases, indicating a more rational pricing environment [2][2] Company-Specific Insights Haidilao - Haidilao's table turnover rate has improved to over 4.0, with expectations for 2026 revenue to reach approximately 4.6 billion yuan [1][5] - The return of founder Zhang Yong as CEO is expected to accelerate the growth of the main brand and the "hard bone" sub-brands, with plans to expand into lower-tier cities and introduce new dining formats [6][6] - If Haidilao maintains a turnover rate above 4.0 and a customer price close to 100 yuan, it could achieve a profit recovery to around 4.6 billion yuan, corresponding to a valuation of about 20 times [6][6] Mixue Ice Cream - Mixue Ice Cream is expected to see over 20% growth in store openings in 2026, with its price advantage under 10 yuan becoming more pronounced as delivery subsidies decline [1][7] - Despite market concerns about same-store sales and growth, Mixue's actual performance may exceed pessimistic expectations, with a stable same-store sales growth forecast [7][8] Songcheng Performance - Songcheng Performance is projected to achieve revenue between 1 billion to 1.1 billion yuan in 2026, driven by improvements in existing projects and new developments [3][4] Old Puhuang Gold - Old Puhuang Gold is transitioning towards a luxury goods model, with expected revenue of around 7.2 billion yuan in 2026 and a low valuation of 15 times [1][10] - The company is focusing on high-value customers, with significant growth potential in its high-end gold product offerings [11][11] China Oriental Education - China Oriental Education has seen a year-on-year increase of over 25% in spring recruitment collections, with a projected profit of 1 billion yuan for 2026 [1][17] - The company is expanding into new sectors such as beauty and pet care, indicating a strategic diversification [17][18] Dongfang Zhenxuan - Dongfang Zhenxuan is experiencing a fundamental turnaround, with plans to expand its self-operated product offerings by 90% to approximately 1,500 SKUs in the 2026 fiscal year [1][18] - The company is enhancing its multi-channel strategy, including expanding its own app and offline teaching networks [18][18] Bluko - Bluko is guiding for a 30% revenue growth in 2026, with a focus on international expansion and new product categories like building vehicles [1][16] - The company aims for a 70%-80% growth in its overseas segment, leveraging popular IPs for market penetration [16][16] Additional Insights - The overall sentiment in the cyclical consumption sector is cautiously optimistic, with signs of recovery in consumer spending and strategic shifts among key players [2][2] - Companies are increasingly focusing on enhancing customer experience and product offerings to drive sales growth in a competitive environment [1][1]

Group 1 - The beauty and personal care sector has shown a slight decline of 0.4% since the beginning of 2026, with significant stock performance variation among key players, ranging from -27.3% to 35.6% [4][12] - The cosmetics market is characterized by intense competition, with domestic brands making significant advancements in R&D and distribution, while international brands are adapting with localized products and flexible marketing strategies [4][20] - The medical beauty sector is witnessing a surge in new products and innovations, with a focus on affordable and specialized offerings, positioning domestic companies to compete effectively against foreign counterparts [4][48] Group 2 - The e-commerce operation segment is undergoing a transformation, with companies like RuYuchen and YiWangYiChuang leveraging self-owned brands and AI to create new growth trajectories [4][43] - Key recommendations for investment include brands with strong channel and product matrices such as MaoGePing and ShangMei, as well as companies like AiMeiKe and LangZi in the medical beauty space [4][45] - The report emphasizes the importance of promotional events like 618 and Double 11, which are critical for brand visibility and sales growth in the competitive online landscape [4][37] Group 3 - The skincare and makeup market is expected to enter a consolidation phase, with strong brands likely to thrive while weaker ones may struggle, particularly in segments like fragrance and hair care [20][21] - Domestic brands are increasingly capturing market share from international brands, with a notable decline in the latter's market presence over recent years [22][27] - The report highlights the strategic importance of product innovation and family series development, as seen with brands like Peiliya, which successfully extend their product lines to enhance sales [28][30]

1. Report Industry Investment Rating - No information provided about the industry investment rating. 2. Core Viewpoints of the Report - The company's online sales channels, including those managed by the Shanghai and Hangzhou teams, have improved in terms of personnel, expertise, and operational efficiency, and the online sales performance meets expectations. The company will continue to recruit professionals to enhance operational efficiency [21]. - The proportion of non - patch products is increasing year by year, and the company will continue to diversify product forms to meet consumer needs [21]. - The online sales proportion has exceeded the offline proportion. The company's offline market has great potential, and it will increase efforts to expand the offline market in the future [21][23]. - The ROI of the Douyin platform improved significantly in 2025 through refined operations, and the company aims to further improve and stabilize it [21]. - In 2025, the company launched dozens of new products, including the Centella asiatica series, the oil - based skin - care series, etc. [23]. - The company has set internal sales targets for 2026 but has no publicly available performance guidance [23]. - The company's recombinant type III humanized collagen freeze - dried fiber has completed clinical trials, and the injection - type recombinant type III humanized collagen gel plans to start clinical trials this year [23]. 3. Summary by Directory 3.1 Research Basic Situation - The research object is Fuerjia. The reception time was on March 17, 2026. The listed company's reception personnel included Director and Board Secretary Deng Baijiao, Securities Affairs Representative Wu Hong, and Investor Relations Management IR Qi Xinxin [16]. 3.2 Detailed Research Institutions - The research institutions include Guohai Securities Co., Ltd. (represented by Li Yuchen), Rongtong Fund Co., Ltd. (represented by Ma Chunxuan), and Caitong Securities (represented by Yang Jiarui). Guohai Securities Co., Ltd. participated twice [17]. 3.3 Research Institution Proportion - No information provided about the research institution proportion. 3.4 Main Content Information - **Sales channels**: The Shanghai team is responsible for interest e - commerce platforms like Douyin, and the Hangzhou team is responsible for shelf e - commerce platforms like Tmall. The offline sales channels are divided into three teams for CS & KA channels, professional channels, and OTC channels [21]. - **Non - patch product proportion**: The proportion of non - patch products is increasing, and the company will continue to diversify product forms [21]. - **Online - offline proportion trend**: Initially, the offline proportion was higher, but now the online proportion has exceeded the offline proportion [21]. - **Douyin ROI**: The ROI on Douyin improved significantly in 2025, and the company aims to further improve and stabilize it [21]. - **New products in 2025**: Dozens of new products were launched, such as the Centella asiatica series, the oil - based skin - care series, etc. [23]. - **Performance guidance**: The company has set internal sales targets for 2026 but has no publicly available performance guidance [23]. - **Medical aesthetic product planning**: The recombinant type III humanized collagen freeze - dried fiber has completed clinical trials, and the injection - type recombinant type III humanized collagen gel plans to start clinical trials this year [23]. - **Offline market outlook**: The offline market has great potential, and the company will increase efforts to expand it in the future [23].

開 拓 藥 業 有 限 公 司 * KINTOR PHARMACEUTICAL LIMITED （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9939） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 自願公告 就KT-939與上美股份簽訂戰略合作框架協議 本公告由開拓藥業有限公司*（「本公司」，連同其附屬公司統稱「本集團」）自願 刊發，以知會本公司股東及潛在投資者有關本集團的最新進展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，近日，本公司全資附屬公司蘇州 開拓藥業股份有限公司（「蘇州開拓」）與上海上美化妝品股份有限公司（一家於 香港聯合交易所有限公司上市的公司（股份代號：2145），「上美股份」）訂立化 妝品領域附帶排他條款的戰略合作框架協議（「框架協議」），內容有關本公司 美白祛斑功效性化妝品原料KT-939的快速商業化。 根據框架協議，蘇州開拓與上美股份就KT-939在中國作為一種化妝品新成分 的註冊與 ...

Investment Rating - Industry rating: Recommended [4] Core Insights - The retail sales of consumer goods in January-February 2026 increased by 2.8% year-on-year, slightly above the consensus expectation of 2.7% [1] - The real estate sector showed significant declines in new construction, completion, sales area, and development investment, with year-on-year decreases of 23.3%, 26.9%, 15.9%, and 10.7% respectively [1][2] - The furniture and cultural office supplies sectors experienced growth rates of 8.8% and 5.8% respectively, indicating a structural recovery in the home goods market [2] - The cosmetics sector saw retail sales of 75.3 billion yuan, with a year-on-year increase of 4.5%, although February faced temporary pressure due to logistics delays and decreased consumer demand [3][6] - The gold and jewelry retail sector reported a retail sales increase of 13.0% year-on-year, supported by rising gold prices and a recovering economy [6] Summary by Category Home Goods - The real estate market is stabilizing, with expectations of recovery supported by ongoing policies and macroeconomic stability [2] - The home goods market is benefiting from trade-in subsidies, activating consumer demand [2] - Key companies to watch include Oppein Home and Mousse, which have strong channel capabilities and product innovation [7] Cosmetics - The cosmetics market is expected to recover, driven by consumer upgrade trends and the upcoming 618 shopping festival [3] - Brands with strong cultural characteristics and clear improvement trends are recommended, such as Maogeping and Lin Qingxuan [7] Gold and Jewelry - The gold and jewelry sector is expected to maintain resilience, particularly among high-end and youth-oriented brands [6] - Companies with strong brand premiums and differentiated pricing models, such as Laopu Gold, are highlighted for investment [7]

Investment Rating - The report assigns a "Buy" rating to the company with a current price of HKD 65.80 and a fair value of HKD 91.95 [5]. Core Insights - The company, Lin Qingxuan, is a leading high-end domestic skincare brand in China, known for its innovative "oil-based skincare" concept. It ranks as the 13th largest high-end skincare brand in China with a market share of 1.4% in 2024 [11][17]. - The company has achieved significant revenue growth, with a CAGR of 32% from 2022 to 2024, and reported a revenue of RMB 1.052 billion in the first half of 2025, representing a year-on-year increase of 98.3% [11][27]. - The company's flagship product, Camellia Oil Essence, has sold over 45 million bottles and has been the top-selling facial oil product in China for 11 consecutive years [11][17]. - The company has successfully integrated an OMO (Online-Merge-Offline) channel model, with 554 stores nationwide, leading the high-end skincare segment in store count [11][17]. Financial Performance - The company's main revenue is projected to grow from RMB 805 million in 2023 to RMB 4.732 billion by 2027, with growth rates of 16.5%, 50.3%, 99.4%, 45.2%, and 35.1% respectively [3]. - EBITDA is expected to increase from RMB 181 million in 2023 to RMB 975 million in 2027, reflecting strong operational efficiency [3]. - Net profit attributable to shareholders is forecasted to rise from RMB 85 million in 2023 to RMB 798 million in 2027, with growth rates of 121.1%, 92.4%, 59.6%, and 39.1% [3]. Market Position and Strategy - Lin Qingxuan has established a strong brand identity through its focus on high-quality ingredients like Camellia and small molecule peptides, with nearly 70% of its revenue coming from high-end products such as essence oils, creams, and serums [11][17]. - The company has leveraged social media platforms like Douyin (TikTok) for rapid growth, achieving a 328% increase in revenue from this channel in the first half of 2025 [11][17]. - The company plans to use proceeds from its IPO to enhance brand value, expand its sales network, and improve production and supply chain capabilities [47][48]. Industry Overview - The Chinese cosmetics market is projected to grow to RMB 688.6 billion by 2024, with skincare products accounting for 67% of this market [51][52]. - The facial oil market is expected to reach RMB 5.3 billion by 2024, with a CAGR of 42.8% from 2019 to 2024, driven by the increasing demand for anti-aging and skin-tightening products [52][59]. - Online sales of skincare products are anticipated to grow significantly, with an expected online penetration rate of 55.3% by 2024 [59].

Investment Rating - The report maintains a "Buy" rating for the company [3][6]. Core Insights - The company is expected to turn profitable in 2025, with a projected net profit of 240 to 290 million yuan, compared to a loss of 830 million yuan in the same period last year. The adjusted net profit is forecasted to be between 38 to 56 million yuan, improving from a loss of 840 million yuan in the previous year [1]. - The anticipated profitability is attributed to the implementation of a focused operational strategy, enhanced brand marketing, and improved product mix leading to higher gross margins. Additionally, non-operating gains from financial assets and investment income are expected to contribute positively [1]. - The company plans to focus on core brands and high-margin product categories, increasing marketing investments and enhancing online channel capabilities. Specific strategies include strengthening the product lineup for the Baicaoji brand and improving operational efficiency across various sales channels [2]. Financial Projections - Revenue forecasts for 2025-2027 are adjusted to 6.349 billion, 7.075 billion, and 7.798 billion yuan, respectively. The projected net profits for the same period are 269 million, 402 million, and 527 million yuan, respectively, indicating significant growth [3][5]. - The company is expected to achieve a year-on-year revenue growth of 11.8% in 2025, with net profit growth of 132.2% [5]. Brand and Product Strategy - The company aims to develop several flagship products that are expected to drive overall brand performance, including the second-generation mosquito repellent from Liushen, Yuze facial cream, and Baicaoji's big white mud, all of which have achieved over 100 million yuan in gross merchandise value [1]. - Marketing efforts will be intensified, with a focus on aligning brand ambassadors with brand positioning and enhancing online sales capabilities through platforms like Douyin and Tmall [2]. Market Position and Valuation - As of March 16, 2026, the company's stock price was 21.66 yuan, with a total market capitalization of approximately 14.56 billion yuan [6]. - The company’s price-to-earnings ratio is projected to be 54.2 in 2025, decreasing to 27.6 by 2027, indicating an improving valuation as profitability increases [5].